The expanded indication includes the intraluminal placement of conventional guidewires beyond stenotic coronary lesions [including CTO] prior to PTCA or stent intervention.
The expanded indication is the result of data generated from the 147-patient FAST-CTOs clinical trial in which the safety and effectiveness of the system in coronary chronic total occlusions was demonstrated.
BridgePoint Medical CEO and president Denis Harrington said the FAST-CTO Trial demonstrated the safety and effectiveness of the CrossBoss Catheter and Stingray System in treating CTOs.
